Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

NCT03838263 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03838263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
July 25, 2019
Completion date
November 20, 2024
Enrollment
62 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

oropharynx cancer